Published in Br J Pharmacol on September 01, 1999
G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol (2011) 1.27
Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg Med Chem (2008) 0.83
Effects of chronic opioid exposure on guinea pig mu opioid receptor in Chinese hamster ovary cells: comparison with human and rat receptor. Biochem Pharmacol (2007) 0.80
Lipo-endomorphin-1 derivatives with systemic activity against neuropathic pain without producing constipation. PLoS One (2012) 0.80
Endomorphin-1 induced desensitization and down-regulation of the recombinant mu-opioid receptor. Br J Pharmacol (2000) 0.75
A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem (1985) 90.20
Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature (1975) 10.33
A simple and sensitive saturation assay method for the measurement of adenosine 3':5'-cyclic monophosphate. Biochem J (1971) 8.85
A potent and selective endogenous agonist for the mu-opiate receptor. Nature (1997) 3.87
Cloning of a delta opioid receptor by functional expression. Science (1992) 3.49
The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci U S A (1992) 2.84
Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc Natl Acad Sci U S A (1979) 2.66
C fragment of lipotropin has a high affinity for brain opiate receptors. Nature (1976) 2.62
Twelfth Gaddum memorial lecture. Drug receptors and the inhibition of nerve cells. Br J Pharmacol (1989) 2.01
Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci U S A (1993) 1.77
Cloning and pharmacological characterization of a rat mu opioid receptor. Neuron (1993) 1.68
Opioid receptor-coupled second messenger systems. Life Sci (1991) 1.58
Molecular biology and pharmacology of cloned opioid receptors. FASEB J (1995) 1.34
Opioid inhibition of Ih via adenylyl cyclase. Neuron (1994) 1.23
Stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor. J Pharmacol Exp Ther (1998) 1.19
Specific G protein activation and mu-opioid receptor internalization caused by morphine, DAMGO and endomorphin I. Eur J Pharmacol (1998) 1.10
Spinal analgesic actions of the new endogenous opioid peptides endomorphin-1 and -2. Neuroreport (1997) 1.04
Mu-opioids activate phospholipase C in SH-SY5Y human neuroblastoma cells via calcium-channel opening. Biochem J (1995) 1.02
Pharmacological modulation of voltage-dependent calcium channels in intact cells. Rev Physiol Biochem Pharmacol (1990) 1.00
Localization of endomorphin-2-like immunoreactivity in the rat medulla and spinal cord. Peptides (1997) 0.97
Immunoreactivity for endomorphin-2 occurs in primary afferents in rats and monkey. Neuroreport (1998) 0.96
Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. J Pharmacol Exp Ther (1998) 0.95
Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex. Peptides (1997) 0.95
Endomorphin-stimulated [35S]GTPgammaS binding in rat brain: evidence for partial agonist activity at mu-opioid receptors. J Neurochem (1998) 0.94
delta- and mu-opioid receptor mobilization of intracellular calcium in SH-SY5Y human neuroblastoma cells. Br J Pharmacol (1996) 0.94
The effects of recombinant rat mu-opioid receptor activation in CHO cells on phospholipase C, [Ca2+]i and adenylyl cyclase. Br J Pharmacol (1997) 0.90
Differential effects of endomorphin-1, endomorphin-2, and Tyr-W-MIF-1 on activation of G-proteins in SH-SY5Y human neuroblastoma membranes. Peptides (1998) 0.90
Distinct inhibitory effects of spinal endomorphin-1 and endomorphin-2 on evoked dorsal horn neuronal responses in the rat. Br J Pharmacol (1997) 0.90
Stimulatory effects of opioids. Br J Anaesth (1998) 0.89
Mobilization of Ca2+ from intracellular stores in transfected neuro2a cells by activation of multiple opioid receptor subtypes. Biochem Pharmacol (1997) 0.89
Endomorphin-1 and endomorphin-2 are partial agonists at the human mu-opioid receptor. Eur J Pharmacol (1998) 0.88
The endogenous mu-opioid receptor agonists endomorphins 1 and 2 have novel hypotensive activity in the rabbit. Biochem Biophys Res Commun (1997) 0.88
Effects of morphine and its metabolites on opiate receptor binding, cAMP formation and [3H]noradrenaline release from SH-SY5Y cells. Biochem Pharmacol (1993) 0.87
Endomorphins inhibit high-threshold Ca2+ channel currents in rodent NG108-15 cells overexpressing mu-opioid receptors. J Physiol (1998) 0.87
Immunofluorescent identification of endomorphin-2-containing nerve fibers and terminals in the rat brain and spinal cord. Neuroreport (1998) 0.86
The stimulatory effects of opioids and their possible role in the development of tolerance. Trends Pharmacol Sci (1996) 0.84
Endomorphin 1 and 2, endogenous ligands for the mu-opioid receptor, decrease cardiac output, and total peripheral resistance in the rat. Peptides (1997) 0.83
Endomorphin 1 and 2, endogenous mu-opioid agonists, decrease systemic arterial pressure in the rat. Life Sci (1998) 0.83
Determinants of the stimulatory opioid effect on intracellular calcium in SK-N-SH and NG108-15 neuroblastoma. Brain Res (1996) 0.82
Ca2+ channel inhibition by endomorphins via the cloned mu-opioid receptor expressed in NG108-15 cells. Eur J Pharmacol (1997) 0.81
Adenylyl cyclase in SH-SY5Y human neuroblastoma cells is regulated by intra- and extracellular calcium. Biochem Pharmacol (1995) 0.80
Parallel stimulations of in vitro and in situ [35S]GTPgammaS binding by endomorphin 1 and DAMGO in mouse brains. Peptides (1998) 0.79
The endogenous mu-opioid agonists, endomorphin 1 and 2, have vasodilator activity in the hindquarters vascular bed of the rat. Life Sci (1997) 0.78
Fentanyl increases intracellular Ca2+ concentrations in SH-SY5Y cells. Br J Anaesth (1996) 0.77
Stimulatory effects of opioids on transmitter release and possible cellular mechanisms: overview and original results. Neurochem Res (1996) 0.76
Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science (1995) 5.74
G-protein-coupled receptor heterodimerization modulates receptor function. Nature (1999) 4.73
Cloning and expression of a rat D2 dopamine receptor cDNA. Nature (1989) 3.59
Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia (2006) 3.23
TRPV3 is a temperature-sensitive vanilloid receptor-like protein. Nature (2002) 3.23
Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol (2001) 3.11
Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. J Neurosci (2000) 2.90
Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth (1996) 2.87
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis (2010) 2.51
Dimerization of the delta opioid receptor: implication for a role in receptor internalization. J Biol Chem (1997) 2.51
A global survey of haplotype frequencies and linkage disequilibrium at the DRD2 locus. Hum Genet (1998) 2.44
Ethanol elicits and potentiates nociceptor responses via the vanilloid receptor-1. Nat Neurosci (2002) 2.43
Mental stress--induced myocardial ischemia and cardiac events. JAMA (1996) 2.20
Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron (1997) 2.20
G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol Ther (2002) 2.18
Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEBS Lett (1994) 2.17
Postoperative nausea and vomiting--time for balanced antiemesis? Br J Anaesth (2000) 2.10
Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci (1998) 1.91
Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol (1993) 1.89
Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell (1997) 1.83
Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci U S A (2001) 1.82
Does shy-inhibited temperament in childhood lead to anxiety problems in adolescence? J Am Acad Child Adolesc Psychiatry (2000) 1.81
Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene (1998) 1.79
Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J Neurosci (1999) 1.69
Cloning and expression of human and rat D1 dopamine receptors. Nature (1990) 1.65
Regurgitation of gastric contents during general anaesthesia using the laryngeal mask airway. Br J Anaesth (1992) 1.64
Trace amine-associated receptors and their ligands. Br J Pharmacol (2006) 1.63
Hypoxaemia during outpatient dental anaesthesia. Anaesthesia (1989) 1.50
Functional interactions between mu opioid and alpha 2A-adrenergic receptors. Mol Pharmacol (2003) 1.49
Orphanin FQ is a functional anti-opioid peptide. Neuroscience (1996) 1.48
Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology (2004) 1.48
Effect of the laryngeal mask airway on lower oesophageal sphincter pressure in patients during general anaesthesia. Br J Anaesth (1992) 1.47
I.v. anaesthetic agents inhibit dihydropyridine binding to L-type voltage-sensitive Ca2+ channels in rat cerebrocortical membranes. Br J Anaesth (1996) 1.44
Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. J Neurochem (1999) 1.43
Identification and characterization of proSAAS, a granin-like neuroendocrine peptide precursor that inhibits prohormone processing. J Neurosci (2000) 1.43
Anandamide: an endogenous activator of the vanilloid receptor. Trends Pharmacol Sci (2000) 1.41
Alcohol preference and sensitivity are markedly reduced in mice lacking dopamine D2 receptors. Nat Neurosci (1998) 1.39
South African guidelines for the management of nocturnal enuresis. S Afr Med J (2003) 1.39
Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. Genomics (1991) 1.38
The interplay between climate change, forests, and disturbances. Sci Total Environ (2000) 1.37
The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci U S A (2001) 1.37
No interaction between the serotonin transporter polymorphism (5-HTTLPR) and childhood adversity or recent stressful life events on symptoms of depression: results from two community surveys. Am J Med Genet B Neuropsychiatr Genet (2007) 1.35
Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more. Trends Neurosci (1998) 1.34
3-Iodothyronamine: a novel hormone controlling the balance between glucose and lipid utilisation. J Comp Physiol B (2007) 1.33
Sequestration of the delta opioid receptor. Role of the C terminus in agonist-mediated internalization. J Biol Chem (1996) 1.31
D2 dopamine receptor gene and obesity. Int J Eat Disord (1994) 1.30
Complete nucleotide sequence of a chicken H2b histone gene. J Biol Chem (1982) 1.30
Amyloid beta-peptide(1-42) and hydrogen peroxide-induced toxicity are mediated by TRPM2 in rat primary striatal cultures. J Neurochem (2005) 1.30
G protein coupled receptor dimerization: implications in modulating receptor function. J Mol Med (Berl) (2001) 1.28
Effect of remifentanil on the haemodynamic response to orotracheal intubation. Br J Anaesth (1998) 1.28
Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation (1997) 1.28
Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat. Br J Pharmacol (1997) 1.28
Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. Eur Neuropsychopharmacol (2008) 1.28
Expression of rat cathepsin S in phagocytic cells. J Biol Chem (1996) 1.27
Flufenamic acid is a pH-dependent antagonist of TRPM2 channels. Neuropharmacology (2004) 1.27
1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorg Med Chem Lett (2001) 1.26
Orexins: a new family of neuropeptides. Br J Anaesth (1999) 1.26
Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ. Neurosci Lett (1996) 1.25
Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine. J Pharmacol Exp Ther (2007) 1.24
Thr353, located within the COOH-terminal tail of the delta opiate receptor, is involved in receptor down-regulation. J Biol Chem (1996) 1.23
Ketamine: new uses for an old drug? Br J Anaesth (2011) 1.23
Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice. Endocrinology (1999) 1.22
The dopamine D4 receptor is essential for hyperactivity and impaired behavioral inhibition in a mouse model of attention deficit/hyperactivity disorder. Mol Psychiatry (2004) 1.22
Remifentanil--an opioid for the 21st century. Br J Anaesth (1996) 1.21
Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J Neurophysiol (2001) 1.21
Opioid receptor endocytosis and activation of MAP kinase pathway. Brain Res Mol Brain Res (2000) 1.19
The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J Neurosci (1999) 1.18
Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist. Br J Pharmacol (2000) 1.18
Morphine compared with diamorphine. A comparison of dose requirements and side-effects after hip surgery. Anaesthesia (1991) 1.18
Identification of peptides from brain and pituitary of Cpe(fat)/Cpe(fat) mice. Proc Natl Acad Sci U S A (2001) 1.18
Characterization using FLIPR of rat vanilloid receptor (rVR1) pharmacology. Br J Pharmacol (2000) 1.18
Effects of remifentanil and alfentanil on the cardiovascular responses to induction of anaesthesia and tracheal intubation in the elderly. Br J Anaesth (2002) 1.17
Dopamine-dependent synaptic plasticity in striatum during in vivo development. Proc Natl Acad Sci U S A (2001) 1.16
Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth (2009) 1.15
Inhibition of TRPM2 channels by the antifungal agents clotrimazole and econazole. Naunyn Schmiedebergs Arch Pharmacol (2004) 1.15
Molecular biology of the dopamine receptors. Eur J Pharmacol (1991) 1.14
Evolution of haplotypes at the DRD2 locus. Am J Hum Genet (1995) 1.14
Persistent postoperative pain: where are we now? Br J Anaesth (2011) 1.13
The peptide orphanin FQ inhibits beta-endorphin neurons and neurosecretory cells in the hypothalamic arcuate nucleus by activating an inwardly-rectifying K+ conductance. Neuroendocrinology (1998) 1.10
Effects of intravenous anesthetic agents on glutamate release: a role for GABAA receptor-mediated inhibition. Anesthesiology (2000) 1.10
Comparison of different doses of remifentanil on the cardiovascular response to laryngoscopy and tracheal intubation. Br J Anaesth (2000) 1.10
Binding and internalization of fluorescent opioid peptide conjugates in living cells. Mol Pharmacol (2000) 1.10
Adrenergic and endothelin B receptor-dependent hypertension in dopamine receptor type-2 knockout mice. Hypertension (2001) 1.09
Cannabinoid activation of recombinant and endogenous vanilloid receptors. Eur J Pharmacol (2001) 1.09
The C-terminal region of proSAAS is a potent inhibitor of prohormone convertase 1. J Biol Chem (2000) 1.09
Molecular mechanisms of opioid receptor signal transduction. Br J Anaesth (1998) 1.09
Animals lacking endothelin-converting enzyme-2 are deficient in learning and memory. Genes Brain Behav (2008) 1.09
Initial experience of percutaneous transhepatic cholangiography using a fine gauge needle. Clin Radiol (1977) 1.08
Ethanol-conditioned place preference is reduced in dopamine D2 receptor-deficient mice. Pharmacol Biochem Behav (2000) 1.08
Inflammatory mediators regulate cathepsin S in macrophages and microglia: A role in attenuating heparan sulfate interactions. Mol Med (1999) 1.08
Longitudinal predictors of behavioural adjustment in pre-adolescent children. Aust N Z J Psychiatry (2001) 1.08
Structure and organization of the chicken H2B histone gene family. Nucleic Acids Res (1987) 1.08
Postoperative myocardial ischaemia: temporal association with nocturnal hypoxaemia. Br J Anaesth (1991) 1.08
Lack of operant ethanol self-administration in dopamine D2 receptor knockout mice. Psychopharmacology (Berl) (2000) 1.07
Opioids and their complicated receptor complexes. Neuropsychopharmacology (2000) 1.07
New ocular hazard of mode locking in CW lasers. Nature (1970) 1.07
Defective prodynorphin processing in mice lacking prohormone convertase PC2. J Neurochem (2000) 1.06
Dopamine D4 receptor-deficient mice display cortical hyperexcitability. J Neurosci (2001) 1.06